Next Issue
Volume 14, December-2
Previous Issue
Volume 14, November-2
 
 

Cancers, Volume 14, Issue 23 (December-1 2022) – 296 articles

Cover Story (view full-size image): A large arsenal of therapeutic options (surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy) has been approved for the treatment of non-small-cell lung cancer (NSCLC). However, patients with advanced NSCLC have an abysmal prognosis due to a propensity to acquire resistance to therapies. In recent decades, much effort has been made to explore the molecular mechanisms at the basis of drug resistance, where microRNAs (small non-coding RNA that regulate gene expression) were found to play key roles. Here, we provide an update of the current knowledge of the role of miRNAs in driving resistance to drugs currently used in the clinic. We also critically discuss how the current experimental approaches can be improved to foster the translation to clinical practice of new discoveries in this field. View this paper
  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Section
Select all
Export citation of selected articles as:
8 pages, 526 KiB  
Article
A Comparison of Skin Staining after Sentinel Lymph Node Biopsy in Women Undergoing Breast Cancer Surgery Using Blue Dye and Superparamagnetic Iron Oxide Nanoparticle (SPIO) Tracers
Cancers 2022, 14(23), 6017; https://doi.org/10.3390/cancers14236017 - 06 Dec 2022
Cited by 4 | Viewed by 1457
Abstract
Superparamagnetic iron oxide nanoparticles (SPIO) are a tracer for sentinel lymph node (SLN) detection. In a preplanned secondary analysis of a prospective clinical trial (SentiDose) we reported on skin staining after SPIO and blue dye (BD) injections. For SPIO, either a 1.5 mL [...] Read more.
Superparamagnetic iron oxide nanoparticles (SPIO) are a tracer for sentinel lymph node (SLN) detection. In a preplanned secondary analysis of a prospective clinical trial (SentiDose) we reported on skin staining after SPIO and blue dye (BD) injections. For SPIO, either a 1.5 mL retroareolar injection on the day of surgery or a 1.0 mL peritumoral/retroareolar injection 1–7 days before surgery was given. A 1.0 mL sub-/intradermal periareolar injection of BD was also administered to all these women. Staining was then assessed at 6, 12 and 24 months after surgery. A total of 270 women received SPIO and were operated on with breast-conserving surgery. Of these, 204 women also received BD. A total of 58 (21.5%) women had an SPIO stain 6 months postoperatively with a median size of 6.8 cm2 (p = 0.56), while 51 (25.0%) had a BD stain with a median size of 8.5 cm2 (p = 0.93). The incidence and size of SPIO and BD staining decreased over time reciprocally. At 24 months, the incidence and median size of SPIO was 23 (8.6%) and 4 cm2, respectively. For BD, the incidence was 14 (6.3%, p = 0.13), and the median size was 3.5 cm2 (p = 0.18). There was, therefore, no statistically significant difference in the incidence or size of skin staining between SPIO and BD over time. Full article
Show Figures

Figure 1

12 pages, 564 KiB  
Article
Early Referral for Breast-Cancer-Related Lymphedema: Do We Follow the Evidence? A Two-Year Prospective Multicenter Cohort Study
Cancers 2022, 14(23), 6016; https://doi.org/10.3390/cancers14236016 - 06 Dec 2022
Viewed by 1202
Abstract
The early detection of breast-cancer-related lymphedema and referral for therapy has the potential to reduce lymphedema-related morbidity. Although research shows the benefits, a gap is observed between evidence and daily practice. We aimed to determine whether the early detection of lymphedema and referral [...] Read more.
The early detection of breast-cancer-related lymphedema and referral for therapy has the potential to reduce lymphedema-related morbidity. Although research shows the benefits, a gap is observed between evidence and daily practice. We aimed to determine whether the early detection of lymphedema and referral for treatment is adequate following the current guidelines. Women with primary breast cancer treated with breast-conserving therapy or ablative treatment were included. Demographic-, general health-, tumor-, and treatment-related data were recorded. Bilateral arm volume measurements were performed preoperatively and 3, 6, 12, and 24 months post-surgery. A 5% or greater Relative Volume Change was considered the cutoff point for lymphedema and as an indication for therapy referral. After 24 months post-surgery, the main outcomes show that among the patients with early signs of lymphedema, based on a Relative Volume Change ≥5%, a nonreferral for therapy was noted in 83%. Additionally, we observed a significant improvement of the mean Relative Volume Change at 24 months within this group, which might implicate that nonreferral was an adequate choice and that watchful waiting is appropriate when lymphedema is detected within the first year post-surgery. Full article
(This article belongs to the Special Issue New Insights in Lymphedema after Cancer to Enhance Clinical Practice)
Show Figures

Figure 1

18 pages, 434 KiB  
Article
Breast Cancer Detection Using Convoluted Features and Ensemble Machine Learning Algorithm
Cancers 2022, 14(23), 6015; https://doi.org/10.3390/cancers14236015 - 06 Dec 2022
Cited by 15 | Viewed by 2042
Abstract
Breast cancer is a common cause of female mortality in developing countries. Screening and early diagnosis can play an important role in the prevention and treatment of these cancers. This study proposes an ensemble learning-based voting classifier that combines the logistic regression and [...] Read more.
Breast cancer is a common cause of female mortality in developing countries. Screening and early diagnosis can play an important role in the prevention and treatment of these cancers. This study proposes an ensemble learning-based voting classifier that combines the logistic regression and stochastic gradient descent classifier with deep convoluted features for the accurate detection of cancerous patients. Deep convoluted features are extracted from the microscopic features and fed to the ensemble voting classifier. This idea provides an optimized framework that accurately classifies malignant and benign tumors with improved accuracy. Results obtained using the voting classifier with convoluted features demonstrate that the highest classification accuracy of 100% is achieved. The proposed approach revealed the accuracy enhancement in comparison with the state-of-the-art approaches. Full article
Show Figures

Figure 1

22 pages, 3182 KiB  
Article
Dual LSD1 and HDAC6 Inhibition Induces Doxorubicin Sensitivity in Acute Myeloid Leukemia Cells
by